New Best Practice Recommendations for SBMA Care in Canada
Congratulations to Dr. Kerri Schellenberg and the team of Canadian experts, including our NMD4C Steering Committee members and Investigators, on publishing the first Canadian SBMA care guidelines!
We congratulate Dr. Kerri Schellenberg and the team of Canadian experts, including our NMD4C Steering Committee members and Investigators, on publishing the first Canadian best practice recommendations for the clinical care of spinal bulbar muscular atrophy (SBMA) in the Canadian Medical Association Journal (CMAJ).
These guidelines provide actionable guidance for multidisciplinary care teams to manage motor and non-motor symptoms, support early diagnosis, and ensure timely referrals to specialized care.
The recommendations were developed by leading Canadian clinicians and researchers, including:
- NMD4C Steering Committe Members: Drs. Lawrence Korngut, Gerald Pfeffer, and Jodi Warman Chardon.
- NMD4C Investigators: Drs. Kerri Schellenberg (Lead), Colleen O’Connell, Christen Shoesmith, Alexandra King, and Malcolm King.
- Additional contributing experts: Drs. Gudrun Caspar-Bell, Colin Ellis, Wendy Johnston, Brendan Kushneriuk, Andrea Lavoie, Reid McGonigle, Julia Newton, Oksana Suchowersky, and Shane Wunder.
These guidelines aim to optimize outcomes and support quality of life for individuals living with SBMA. We encourage you to share this important publication with your networks.
Read next...
NMD4C Hosts 3rd Annual Basic Research Summer School at uOttawa!
From June 8 to 10, 2026, we hosted the 3rd annual NMD4C Basic Research Summer School at the University of Ottawa. The program supported 28 neuromuscular research trainees (graduate students and postdoctoral fellows) from across Canada and focused on developing practical skills, strengthening core knowledge in neuromuscular research, and providing opportunities to present and discuss their work. Through a combination of tutorials, lectures, hands-on workshops in cutting-edge wet lab techniques, flash talks, and both structured and informal networking, participants engaged with faculty, exchanged ideas, and built connections across institutions and career stages.
New Publication from the NMD4C Clinical Trial Network Strengthens Trial Capacity in Canada
We are pleased to share a new publication from the NMD4C Clinical Trial Network led by Kerri Lynn Schellenberg, Homira Osman, Maria Masnata, Rhiannon Hicks, Corinne Kagan, Ana Stosic, Stacey Lintern, Erin Beattie, Drs. Hanns Lochmüller, Craig Campbell, and Jean K Mah. This work focuses on the implementation of a coordinated Canadian neuromuscular clinical trial network to enhance trial readiness, capacity, and access in rare disease research.
Canadian-Led Phase II Studies Advance Vamorolone Evidence in Duchenne Muscular Dystrophy
NMD4C investigators contributed to two phase II studies evaluating vamorolone in boys with Duchenne muscular dystrophy across early childhood and adolescence, demonstrating safety, favorable pharmacokinetics, and potential efficacy. Led by Dr. Jean Mah and conducted across Canadian clinical trial sites with national and industry collaborators, the findings supported Health Canada approval of vamorolone as the first treatment for DMD in Canada. Leaders from both the clinical and patient advocacy communities, including Defeat Duchenne Canada, highlighted the impact of collaboration among patients, families, clinicians, and researchers in advancing care and improving access to new therapies.